GMT EIGHT - Stocks - HK Stock

IMMUNEONCO-B (01541) successfully recruited 133 patients for the mid-term analysis of the Phase III clinical trial of IMM01 (decitabine) for first-line treatment of chronic myelomonocytic leukemia (CMML).

Yimengangke-B (01541) announced that the company has successfully completed the recruitment of 133 patients for the mid-term analysis of the Phase III clinical trial of IMM01 (idarubicin liposome) for the first-line treatment of chronic myelomonocytic leukemia (CMML).

Sinopharm (01099) announced its annual performance with a net profit attributable to owners of the company of 7.155 billion yuan, an increase of 1.5% year-on-year. The final dividend is 0.69 yuan per share.

China National Pharmaceutical Group (01099) announced its annual results for the year ending on December 31, 2025. The group achieved a revenue of RMB 575.168 billion (all in the same unit), a decrease of 1.6% year-on-year. The attributable profit to equity holders of the parent company was RMB 7.155 billion, an increase of 1.5% year-on-year. Earnings per share were RMB 2.29, with a proposed final dividend of RMB 0.69 per share.

New stock news | Guangzhou Tinci Materials Technology (002709.SZ) Hong Kong IPO prospectus invalid

Guangzhou Tianci Advanced Materials Co., Ltd. (referred to as Tianci Materials, 002709.SZ) submitted its Hong Kong IPO prospectus on September 22, 2025, which expired on March 22, 2026, after 6 months.

New Stock News | GEM Co., Ltd. (002340.SZ) Hong Kong Stock IPO prospectus has become invalid.

Green Beauty Co., Ltd. (referred to as Green Beauty (002340.SZ))'s Hong Kong IPO prospectus submitted on September 22, 2025 expired after 6 months on March 22, 2026.

New stock news | Zhongshan Broad-ocean Motor (002249.SZ) Hong Kong IPO prospectus expired

The Hong Kong prospectus submitted by Zhongshan Deyang Electric Motor Co., Ltd. (referred to as Deyang Electric Motor, 002249.SZ) on September 22, 2025, expired after 6 months on March 22, 2026.

APAC RESOURCES (01104) had a comprehensive net asset value per share of approximately HKD 5.33 at the end of January.

Asia Pacific Resources (01104) announced that, as of January 31, 2026, based on the unaudited comprehensive management accounts of the company and the market value of listed investments (adjusted to reflect the market price of investments in listed associates), the unaudited comprehensive net asset value per share of the company is approximately 5.33 Hong Kong dollars.

New Stock News | Fujian Wanchen Food Group (300972.SZ) Hong Kong IPO prospectus has been invalidated.

The Hong Kong IPO prospectus submitted by Fujian Wanchen Biotechnology Group Co., Ltd. (referred to as Wanchen Group, 300972.SZ) on September 23, 2025, expired after 6 months on March 23, 2026.

New stock news | China Micro Semicon (Shenzhen) (688380.SH) The Hong Kong IPO prospectus is invalid.

The Hong Kong IPO prospectus submitted by Zhongwei Semiconductor (Shenzhen) Co., Ltd. (referred to as Zhongwei Semiconductor (688380.SH)) on September 23, 2025, expired on March 23, 2026, after being valid for 6 months.

REGAL INT'L (00078) subsidiary intends to sell 100% of the equity of Chasehill Limited.

REGAL INT'L (00078) announced on March 20, 2026, that Seller R-REIT Asset Holdings (Oriental) Limited, Rich Day (a wholly owned subsidiary of Rich Day Industrial Trust (018881)), the guarantor (in its capacity as trustee of Rich Day Industrial Trust), and Buyer Lidan Property have entered into a preliminary sale and purchase agreement. The Seller has agreed to sell, and the Buyer has agreed to purchase, the sole issued share of the target company at the sale share price; and the Seller has agreed to transfer, and the Buyer has agreed to accept the transfer of the sale loan at the sale loan price (based on the agreed property value of Rich Day Oriental Hotel at 1.518 billion Hong Kong dollars).

Copper Master (00664) will start its IPO from March 23 to March 26, planning to globally issue 7.4068 million H shares.

Copper Master (00664) is scheduled to go public from March 23 to March 26, 2026. The company plans to globally offer 7.4068 million H shares, with 10% allocated for sale in Hong Kong and 90% for international sale, along with an additional 15% for over-allotment option. The offering price per share is set at HK$60-68, with a minimum trading lot of 100 shares. It is expected that trading of H shares will commence on the Stock Exchange of Hong Kong at 9:00 am on March 31, 2026 (Tuesday).

On March 23 to March 26, Fourier (03625) conducted its IPO, planning to globally issue 12 million H shares.

Furui (03625) will be listed from March 23 to March 26, 2026. The company plans to globally sell 12 million H shares, with 5% sold in Hong Kong and 95% sold internationally, with an additional 15% of over-allotment option. The offer price is 40-50 Hong Kong dollars per share, with a minimum of 100 shares per lot. It is expected that the H shares will begin trading on the Hong Kong Stock Exchange at 9:00 am on March 31, 2026 (Tuesday).

ST Holdings (08305) issued a profit warning, expecting the comprehensive loss for the year 2025 to increase by no less than 19 million Hong Kong dollars compared to the previous year.

Saint Tang Holdings (08305) announced that the Group is expected to incur a comprehensive loss of not less than approximately 19 million Hong Kong dollars for the year ending December 31, 2025, while the loss for the year ending December 31, 2024 was approximately 3.1 million Hong Kong dollars.

CLOVER BIO-B(02197): Clover Hong Kong has entered into a settlement agreement with the Global Vaccine Immunization Alliance.

Trifolium Biopharma-B (02197) issued an announcement regarding the Global Vaccine Immunization Alliance's termination notice of the pre-purchase agreement with Trifolium Biopharma (Hong Kong) Limited (a wholly-owned subsidiary of the Company, "Trifolium Hong Kong") and a claim letter demanding the return of $224 million prepayment amount; as well as the Global Vaccine Immunization Alliance filing for arbitration to recover said prepayment amount. Trifolium Hong Kong and the Global Vaccine Immunization Alliance entered into a settlement agreement on March 22, 2026, whereby the arbitration will be fully and finally resolved. All claims made by the Global Vaccine Immunization Alliance against Trifolium Hong Kong in the arbitration will be withdrawn and discharged after payment of the preliminary amount as specified below.

NEW GONOW RV (00805) is expected to have a net profit of approximately 31 to 40 million yuan in the fiscal year 2025, a year-on-year decrease of about 12.07% to 31.85%.

Xinjiao RV (00805) announced that the group's internal net profit for the fiscal year ending December 31, 2025 is expected to be approximately RMB 31 million to RMB 40 million, a decrease of about 12.07% to 31.85% from the net profit of RMB 45.49 million for the fiscal year ending December 31, 2024. This is due to the following factors:

Yum China (09987) spent HK$7.7113 million on March 20 to buy back 18,400 shares.

Panda Retail Company (09987) announced on March 20, 2026 to spend $2,999,980 to repurchase 57,500 shares; and spend HK$7,711,300 to repurchase 18,400 shares.

Chifeng Jilong Gold Mining (06693) will distribute a final dividend of 0.32 yuan per share on June 1st.

Chifeng Gold (06693) announced that it will distribute a final dividend of HK$0.32 per share for the year ending December 31, 2025, payable on June 1, 2026.

Zijin Gold International (02259) will distribute a final dividend of HK$1.5 per share on June 26th.

Purple Gold International (02259) announced that it will distribute a final dividend of HK$1.5 per share for the year ending December 31, 2025, to be paid on June 26, 2026.

BOSS ZHIPIN-W (02076) issues 2.89764 million shares as rewards.

BOSS Zhipin -W (02076) announces that on March 21, 2026, the company granted a total of 2.89764 million restricted share units to 70 employees as part of the initial public offering plan, representing the same number of Class A common shares.

Chifeng Jilong Gold Mining (06693) plans to rename to "Chifeng Jilong Gold Mining Group Co., Ltd."

Chifeng Gold (06693) announces that the Board of Directors suggests changing the Chinese name of the company from "Chifeng Jilong Gold Mining Co., Ltd." to "Chifeng Jilong Gold Mining Group Limited", and changing the English name of the company from "Chifeng Jilong Gold Mining Co., Ltd." to "Chifeng Jilong Gold Mining Group Limited". The stock code, English stock abbreviation, and Chinese stock abbreviation of the company will remain unchanged.

ZIJIN GOLD INTL (02259) announces annual performance, with a net profit attributable to shareholders of 1.602 billion US dollars, a year-on-year increase of 232.71%.

China Gold International Resources (02259) released its annual performance as of December 31, 2025. The group achieved revenue of 5.383 billion US dollars, an increase of 80.05% year-on-year; net profit attributable to shareholders was 1.602 billion US dollars, an increase of 232.71% year-on-year; basic earnings per share were 0.82 US dollars. It plans to pay a final dividend of 1.5 Hong Kong dollars per share in cash.

MNSO (09896) repurchased 55,600 shares at a cost of 227,300 USD on March 20th.

Miniso (09896) announced that it will repurchase 55,600 shares at a cost of $227,300 on March 20, 2026.

Chifeng Jilong Gold Mining (06693) released its annual performance, with a net profit attributable to owners of the company of 3.082 billion yuan, an increase of 74.7% year-on-year.

Chifeng Gold (06693) announced its annual performance ending on December 31, 2025. The group achieved a revenue of 12.639 billion yuan, a year-on-year increase of 40.03%; the net profit attributable to the parent company was 3.082 billion yuan, a year-on-year increase of 74.7%; and the basic earnings per share were 1.69 yuan. It is proposed to distribute a cash dividend of 0.32 yuan per share at the end of the period.

PERSISTENCEGOLD(02489): Yantai Moujin resumes production

Jiuhai Gold (02489) issued a statement regarding the temporary suspension of production at Yantai Moujin. The company hereby announces that as of the date of this announcement, Yantai Moujin has resumed production. The Board of Directors believes that the temporary suspension of production at Yantai Moujin will not have a significant impact on the Group's annual gold production, as the downtime was relatively short.

Zijin Mining Group (02899) will distribute a final dividend of 3.8 yuan for every 10 shares.

Zijin Mining (02899) announced that it will distribute a final dividend of RMB 3.8 per 10 shares for the year ending on December 31, 2025.

ZHAOJIN MINING (01818) will distribute a final dividend of 0.1 yuan per share on June 30th.

Zhaokin Mining (01818) announced that it will distribute a final dividend of 0.1 yuan per share for the year ending December 31, 2025, payable on June 30, 2026.

SINOPEC CORP(00386) will distribute a final dividend of 0.112 yuan per share on June 26th.

China Petroleum & Chemical Corporation (00386) announced that it will distribute a final dividend of 0.112 yuan per share for the year ending December 31, 2025, to be paid on June 26, 2026.

ZHAOJIN MINING (01818) announced its annual performance with a net profit attributable to shareholders of 3.614 billion yuan, an increase of 149.1% year-on-year. All major indicators saw significant growth, reaching a new historical high.

Zijin Mining (01818) announced its full-year performance for the year ending December 31, 2025. The group achieved a revenue of RMB 18.056 billion, representing a year-on-year increase of 56.32%; net profit attributable to shareholders was RMB 3.614 billion, a year-on-year increase of 149.1%; basic earnings per share were RMB 0.96. A cash dividend of RMB 0.1 per share is proposed to be distributed.

CA CULTURAL (01566) announces its interim results with a shareholder loss of HKD 66.245 million, representing a year-on-year increase of 3410.6%.

Huaxia Culture Technology (01566) announced its interim results for the six months ended September 30, 2025. The Group generated revenue of HK$165 million, a decrease of 14.37% year-on-year. The company's attributable loss to owners amounted to HK$66.245 million, an increase of 3410.6% year-on-year, with basic loss per share of 5.6 HK cents.

SINOPEC CORP (00386) releases annual performance with a net profit attributable to shareholders of 31.809 billion yuan, a year-on-year decrease of 36.8%.

China Petroleum and Chemical Corporation (00386) announced its annual performance for the year ending December 31, 2025. The company achieved operating revenue of 2,835.83 billion yuan (RMB, same below), a decrease of 9.5% year-on-year; net profit attributable to shareholders was 31.809 billion yuan, a decrease of 36.8% year-on-year; basic earnings per share was 0.262 yuan. It is proposed to distribute a final cash dividend of 0.112 yuan per share (including tax).

BESUNYEN (00926) reported an annual profit attributable to shareholders of 20.44 million yuan, an increase of 38.09% year-on-year.

Beijing Tong Ren Tang (00926) announced its annual results for the year ending December 31, 2025. The group recorded a revenue of 494 million yuan, an increase of 2.07% year-on-year. The company's net profit attributable to owners for the year was 204.43 million yuan, an increase of 38.09% year-on-year. Earnings per share were 0.17 yuan.

SIHUAN PHARM (00460): The Phase III clinical trial of Esmoprazole Sodium Enteric-Coated Tablets (Anjiuwei) for the treatment of reflux esophagitis in China has completed the enrollment of all subjects.

Sihuan Pharmaceutical Holdings Group Limited (00460) announced that its non-wholly owned subsidiary, Xuanzhu Bio-Tech Co., Ltd. (stock code: 02575.HK), has successfully completed the China Phase III clinical trial of its innovative drug Anilanaz Sodium Enteric-coated Tablets (trade name: Anjiuwei) for the treatment of adult reflux esophagitis (RE) with all 500 subjects enrolled.

SHANGHAI GROWTH (00770): Successfully placed 2.187 million shares of rights issue.

SHANGHAI GROWTH (00770) announced that as of 4:00 pm on March 4, 2026, the deadline for accepting the final subscription for shares and payment, a total of 5 valid applications were received, involving a total of 2.12 million shares of shares subscribed, equivalent to approximately 55% of the total number of shares proposed under the subscription.

BOYAA (00434) plans to seek approval from shareholders in advance to grant purchase authorization for a total amount of encrypted currency not exceeding 70 million US dollars.

Boya Interactive (00434) released an announcement, indicating that in order to continue strengthening the company's Web3 strategic layout, it is advisable to use the group's idle funds reserve in the downturn of the cryptocurrency market to appropriately expand the allocation of cryptocurrencies, thereby further enhancing the development of the company's Web3 business.

BRONCUS-B(02216) plans to further acquire 3.85% equity of Valgen Holding Corporation for 55.12 million US dollars.

Kunbo Medical-B (02216) announced that on March 21, 2026, the buyer Broncus China Holding Corporation (a wholly-owned subsidiary of the company) and the seller Max Grand Limited entered into a share transfer agreement. Pursuant to this agreement, the seller conditionally agreed to sell, and the buyer conditionally agreed to purchase, the target shares of Valgen Holding Corporation (representing 3.85% of the issued and outstanding shares of the target company as of the date of this announcement) for a total consideration of 55.12 million US dollars.

XUANZHUBIO-B(02575): Omeprazole enteric-coated tablets (Anjiuwei) completed the enrollment of all subjects in the Phase III clinical trial for the treatment of reflux esophagitis in China.

Xuanzhu Bio-B (02575) announced that the company's independently developed innovative drug Anelazol Sodium enteric-coated tablets (trade name: Anjiuwei) for the treatment of adult gastroesophageal reflux disease (RE) has successfully completed the enrollment of all 500 subjects in the Phase III clinical trial in China.

CA CULTURAL (01566) releases annual performance. Shareholders' net loss was HKD 33.043 million, a year-on-year decrease of 80.64%.

Huaxia Culture Technology (01566) announced its annual performance for the year ending March 31, 2025. The group achieved revenue of 367 million Hong Kong dollars, a year-on-year increase of 0.81%; the company's owners' equity loss was 33.043 million Hong Kong dollars, a year-on-year decrease of 80.64%; basic loss per share was 0.028 Hong Kong dollars.

WKK INTL (HOLD)(00532): Zhang Ruishen resigns as executive director.

WKK INTL (HOLD) (00532)announced that Mr. Zhang Ruishen will resign from the position of Executive Director of the company starting from March 21, 2026 due to the company's restructuring. In addition, Mr. Zhang will no longer serve as a director and president of the company's subsidiary, Wangshi Gangjian Distribution Co., Ltd.

SINOPEC CORP (00386): Wan Tao appointed as President and Authorized Representative

China Petroleum & Chemical Corporation (00386) announced that Mr. Zhao Dong has resigned as the President and authorized representative of the company due to a job adjustment, and has been appointed as a non-executive director of the company, while still serving as the Vice Chairman. Mr. Wan Tao has been appointed as the new President and authorized representative of the company. It is recommended to elect Mr. Tian Hongbin as an executive director of the company, subject to approval by the shareholders' meeting, and Mr. Tian has also been appointed as a Senior Vice President of the company. Mr. Xiong Xiaoyang has been designated as the representative in Hong Kong to accept legal documents and notices in accordance with the Securities Listing Rules and the Company's Articles of Association of the Hong Kong Stock Exchange.

GRAND PHARMA(00512): The global innovative product TP-03 for the treatment of demodex blepharitis has been approved for market in China.

Yuanda Medical (00512) announced that the group has introduced the global innovative ophthalmic drug GPN01768 "TP-03 (Loteprednol Eye Drops) 0.25%" for the treatment of demodex blepharitis, and it has recently officially obtained the drug registration certificate issued by the National Medical Products Administration of China. During the drug review process, no supplementary information notice was received, and the approval for marketing was achieved without any further requirements.

GRAND PHARMA (00512) is the only company in the world that has been granted approval for the treatment of Demodex blepharitis. Global sales are rapidly increasing, with peak sales potentially exceeding 2 billion US dollars!

On March 22, Faraday Pharmaceuticals (00512), a technology-innovative international pharmaceutical company listed on the Hong Kong Stock Exchange, announced positive news. The company's innovative eye medicine product line has added another heavyweight product - GPN01768 (TP-03, (Loratadine Eye Drops) 0.25%), a global innovative ophthalmic drug for the treatment of Demodex blepharitis, has officially been approved for sale in the domestic market. During the drug evaluation process, no supplementary information notice was received, achieving "zero supplemental approvals". It is expected that the peak sales of this product will exceed 2 billion US dollars, and this product is expected to become another popular single product for Faraday Pharmaceuticals.

China Galaxy Securities: Investing in Three Main Themes in the Hong Kong Stock Market Amid Geopolitical Conflicts and High Oil Prices

Looking ahead to the future, if the US and Iran get entangled in a long-term conflict, the Hong Kong stock market will experience a three-stage evolution of "short-term emotional impact medium-term fundamental transmission long-term structural differentiation".

New stocks interpretation | With a 1193.68 times oversubscription, can the rapid innovation of Feisu (03355) DTC model support a premium for "hard technology"?

In just one short year, the rapidly innovating valuation has increased by nearly 2.7 times. With the valuation already substantially increased, how much growth space is left for the secondary market?

WeChat releases official lobster plugin, Tencent Cloud is the first to adapt.

Currently, the WeChat ClawBot plugin is "gradually increasing volume" and needs to be updated to the latest version.

One chart to understand CHINAHONGQIAO's (01378) 2025 annual performance: revenue increased by 4% year-on-year, continuous optimization of financial structure.

The group's performance in 2025 is strong, with revenue increasing by 4% year-on-year to 162.35 billion yuan, and net profit attributable to shareholders increasing by 1.2% year-on-year to 22.64 billion yuan.

New Stock News | Indonesia's MGR Files for Listing on Hong Kong Stock Exchange as One of Asia's Top Pure Gold Producers.

According to the disclosure by the Hong Kong Stock Exchange on March 20, PT Merdeka Gold Resources Tbk (referred to as MGR) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with UBS and Citic Securities serving as its joint sponsors.

New stock news | PT Merdeka Gold Resources Tbk files for listing on the Hong Kong Stock Exchange

According to the disclosure on March 20 by the Hong Kong Stock Exchange, PT Merdeka Gold Resources Tbk (abbreviated as MGR) has submitted a listing application to the Main Board of the Hong Kong Stock Exchange, with UBS and CITIC Securities as its joint sponsors.

New stock news | New Element Pharma submits a second filing to the Hong Kong Stock Exchange. Its core product ABP-671 is a new generation URAT1 inhibitor.

According to the disclosure on March 20th by the Hong Kong Stock Exchange, Hangzhou New Element Pharmaceutical Co., Ltd. (referred to as New Element Pharmaceutical) has submitted its listing application to the Main Board of the Stock Exchange, with CITIC Securities as its sole sponsor. This is the company's second submission to the Hong Kong Stock Exchange.

New stock news | New Element Pharmaceuticals files for a second time with the Hong Kong Stock Exchange.

According to the disclosure on March 20th by the Hong Kong Stock Exchange, Hangzhou New Element Pharmaceutical Co., Ltd. (referred to as New Element Pharmaceutical) has submitted a listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor.

Energy storage is Token, GUOXIA TECH (02655) 2025 full-year performance greatly exceeds expectations, income soars as AI computing power demand increases exponentially!

Guo Xia Technology saw explosive growth in annual revenue from 1.42 billion in 2022 to 20.57 billion in 2025, achieving nearly 15 times compound high growth.

HK Bull/Bear Outstanding Qty Ratio(65:35) | March 21st

As of March 21, the latest bull-bear ratio of the Hang Seng Index is 65:35.

Seeking Coverage

Being Writer

Exploring Cooperation